STEVENSON, Md., July 13, 2017 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Axiom Holdings, Inc. (OTCQB:AIOM) (“Axiom” or the “Company”) securities during the period between October 14, 2016 and June 19, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until August 21, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Axiom securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Axiom lacked control over the merger process sufficient to ensure that the agreement with CJC Holdings, Ltd. (“CJC”) would be completed, the agreement was never completed, and the issuance of shares to the CJC shareholders was improper.
According to the complaint, following a June 19, 2017 announcement that the Company has identified discrepancies related to prior news announcements in response to a subpoena from the U.S. Securities and Exchange Commission and that the Company would rescind shares related to CJC reverse merger, the value of Axiom’s shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Axiom securities purchased on or after October 14, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]


Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 



